InterveXion Therapeutics
InterveXion is a privately-held clinical-stage biopharmaceutical company developing novel product candidates for the treatment of addiction disorders. Their lead clinical asset is IXT-m200, a monoclonal antibody directed against methamphetamine, which acts by re-partitioning methamphetamine away from its sites of action in the CNS. IXT-m200 has received US FDA Fast Track Designation, and is being studied in an ongoing Phase 2 proof-of-concept study (STAMPOUT; NCT03336866). They are also developing a novel vaccine (IXT-v100) against methamphetamine, which is in Preclinical Development.
Domain
intervexion.com
Country
United StatesIndustry
Addiction TreatmentEmployees
1-10
Last Funding
$13.8M
Founded
2003
Tech Stack (1 technologies)
Frequently Asked Questions
What technologies does InterveXion Therapeutics use?+
InterveXion Therapeutics uses 1 technologies including Amazon ALB.
What industry is InterveXion Therapeutics in?+
InterveXion Therapeutics operates in the Addiction Treatment industry.
Where is InterveXion Therapeutics based?+
InterveXion Therapeutics is headquartered in United States.
Need this data at scale?
Get ready-to-use datasets: companies, technologies, and tech adoption signals across 3M+ websites.
Browse DatasetsData last updated: June 2026